check_circleStudy Completed

Diabetes Mellitus

Bayer Identifier:

15316

ClinicalTrials.gov Identifier:

NCT01248481

EudraCT Number:

Not Available

EU CT Number:

Not Available
GlucoFriend-evaluation the effectiveness of Glucobay when combined with a basal insulin

Trial purpose

To evaluate the effectiveness of Glucobay when combined with a basal insulin under daily-life treatment conditions in a large sample of Korean patients.

Key Participants Requirements

Sex

Both

Age

18 - N/A
  • - Signed written informed consent
    - Age ≥ 18 years
    - Diagnosed of type 2 diabetes for at least 6 months prior to enrollment
    - Patients treated with stable dose of a basal insulin (insulin glargine or insulin detemir) at least 2 months
    - HbA1C≥7.5 and ≤10.0%

  • - Exclusion criteria must be read in conjunction with the local product information

Trial summary

Enrollment Goal
539
Trial Dates
September 2010 - July 2012
Phase
N/A
Could I Receive a placebo
No
Products
Acarbose (Precose/Glucobay, BAYG5421)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Many Locations, Korea, Republic Of

Primary Outcome

  • Change in HbA1c
    date_rangeTime Frame:
    After 20 weeks
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • Duration and dose of acarbose treatment
    date_rangeTime Frame:
    After 20 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Postprandial Blood Glucose
    date_rangeTime Frame:
    After 20 weeks
    enhanced_encryption
    Safety Issue:
    No

Trial design

Combined use of a basal insulin and Glucobay For reducing PPG to end diabetes progress
Trial Type
Observational
Intervention Type
Drug
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.